RICOVR’s patented testing platform leverages the first truly portable nanoparticle detection technology, allowing for fast, non- invasive specimen collection and analytics. With the collaboration of industry experts, the company’s platform is versatile and already expanding into new testing diagnostics including COVID-19, additional drug panels, and critical disease testing.

RICOVR is driven by the belief that a more accurate and cost-effective solution should be  available for employers, law enforcement, healthcare systems and others relying on fast and reliable access to data.